Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
Location status: Recruiting
Location contact
Chrisandra Shufelt, MD
PRINCIPAL_INVESTIGATOR
Lauren Uy
CONTACT
Tina Taaffe
CONTACT
NCT Number: NCT07218445
The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.
Interested in participating?
Request Info46 year–60 year
Female
Interventional
Phase 4
Jacksonville, Florida, 32224, United States
Location status: Recruiting
Chrisandra Shufelt, MD
PRINCIPAL_INVESTIGATOR
Lauren Uy
CONTACT
Tina Taaffe
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tirzepatide will be administered with a starting dose of 2.5 mg weekly, subcutaneously injected. The dose will increase by 2.5 mg every 4 weeks until reaching 15 mg.
Participants will be asked to follow lifestyle interventions:
A placebo for Tirzepatide will be administered with a starting dose of 2.5 mg weekly, subcutaneously injected. The dose will increase by 2.5 mg every 4 weeks until reaching 15 mg.
Participants will be asked to follow lifestyle interventions:
Time frame: Baseline, 24 weeks
Change in the frequency of self-reported daily average vasomotor symptoms from baseline to 24 weeks. Vasomotor symptoms will be captured for 2 weeks at baseline and 2 weeks at the end of the study.
Time frame: Baseline, 24 weeks
Change in self-reported daily vasomotor symptom severity from baseline to 24 weeks. Vasomotor symptoms will be captured for 2 weeks at baseline and at the end of the study. Severity will be classified as follows:
Mild, sensation of heat without sweating/dampness; Moderate: sensation of heat with sweating/dampness, but able to continue current activity. May briefly fan yourself; Severe: sensation of intense heat with sweating causing disruption of current activity.
Time frame: 24 weeks
Cellular senescence markers are measured in plasma samples to assess biological aging and cellular stress. These markers may include proteins associated with the senescence-associated secretory phenotype (SASP). Quantification is performed using immunoassays. Higher levels of senescence markers indicate increased cellular senescence.
Time frame: 24 weeks
Epigenetic clocks estimate biological age by analyzing DNA methylation patterns at specific CpG sites across the genome. Biological age estimates are compared to chronological age to assess aging acceleration or deceleration. Biological age greater than chronological age indicates accelerated biological aging and potential increased risk of morbidity and mortality. Primary measure is the difference (ΔAge) between biological and chronological ages = reported in years.
Time frame: Baseline, 12 weeks and 24 weeks
Vascular function will be measured using the EndoPAT device to assesses reactive hyperemia index (RHI) from baseline to week 24 on treatment or placebo. RHI is automatically calculated through a computer algorithm by following the equation: [(tested arm-post occlusion/tested arm-baseline)/(control arm-post occlusion/control arm-baseline)] × baseline correction factor. Endothelial dysfunction is defined as having an RHI ratio of equal or less than 1.67.
Time frame: Baseline, 12 weeks, and 24 weeks
Augmentation Index (AIx): AIX uses applanation tonometry of the radial artery pulse, calibrated to resting brachial systolic and diastolic pressures (SphygmoCor XCEL, Medtronic, Minneapolis, MN). Aortic systolic, diastolic, and pulse pressures will be derived from a synthesized aortic waveform using a validated mathematical transfer function. Augmentation pressure, reflecting the difference between aortic systolic pressure and the inflection point caused by the reflected wave, is influenced by arterial stiffness as well as factors like heart rate and ejection dynamics. AIx is calculated as augmentation pressure divided by aortic pulse pressure × 100%, adjusted to a heart rate of 75 bpm (AIx@75 bpm). Measurements will be performed in duplicate and averaged.
Time frame: Baseline, 12 weeks, and 24 weeks
SphygmoCor estimates central arterial stiffness by calculating the speed at which the pressure wave travels between the carotid and femoral arteries using applanation tonometry and reported as the pulse wave velocity (PWV); PWV m/s
Time frame: Baseline, 24 weeks
Change in cardiometabolic parameters including blood pressure from baseline to week 24 on treatment or placebo. Measured in mmhg
Time frame: Baseline, 24 weeks
Change in cardiometabolic parameters including fasting glucose from baseline to week 24 on treatment or placebo. Measured in mg/dL
Time frame: Baseline, 24 weeks
Change in cardiometabolic parameters including HbA1C from baseline to week 24 on treatment or placebo. Measured in %
Time frame: Baseline, 24 weeks
Change in cardiometabolic parameters including Lipoprotein profile from baseline to week 24 on treatment or placebo. Measured in mg/dL
Time frame: Baseline, 24 weeks
Change in cardiometabolic parameters including hsCRP from baseline to week 24 on treatment or placebo. Measured in mg/L
Time frame: Baseline, 24 weeks
The SPPB is a standardized test that evaluates lower extremity function using three components: balance tests (standing in various positions), gait speed (walking a short distance), and chair stand (repeated standing from a seated position). Each component is scored from 0 to 4; the total score ranges from 0 to 12. Higher scores represent better physical function
Time frame: Baseline, 24 weeks
The mCTSIB assesses balance under four sensory conditions: eyes open/closed on firm and foam surfaces. Testing is performed while standing on the RAPID foot pressure mat, which captures center of pressure and postural sway data. The primary measure is average sway area of the four sensory conditions. The sway area is the area which is required to correct equilibrium, representing the total area covered by postural sway, measured in square centimeters (cm²).
Time frame: Baseline, 24 weeks
This test evaluates upper body muscular power. Participants perform a two-handed chest throw of a 2-kg medicine ball from a standing position. The MST is used to record throw distance, velocity, and related performance metrics. The primary measure is Peak Power Score (W).
Time frame: Baseline, 24 weeks
This test assesses lower body strength and function. Participants are instructed to stand up from a chair and sit back down five times without using their arms. The MST measures movement dynamics. The primary measure is peak power score (W).
Time frame: Baseline, 24 weeks
The 6MWT is a standardized submaximal exercise test used to assess functional aerobic capacity. Participants are instructed to walk as far as possible in six minutes along a flat, straight course. The total distance walked is recorded in feet. Longer walking distances indicate better aerobic capacity and endurance.
Time frame: Baseline, 24 weeks
Participants are instructed to squeeze the dynamometer with maximum effort, measured in kilograms. The highest value from multiple trials is recorded.
Contact information is provided by the study sponsor or research team.
Mayo Clinic
Other
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity: A Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01141972
Adnexal Diseases, Avitaminosis
Portland, Oregon, United States
View Trial DetailsNCT07407348
Body Weight, Healthy
Nottingham, United Kingdom
View Trial DetailsNCT07564414
Body Weight, Diabetes Mellitus
Birmingham, Alabama, United States
View Trial DetailsNCT07497880
Body Weight, Diabetes Mellitus
Chandler, Arizona, United States
View Trial Details